Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $218.11 USD
Change Today +2.32 / 1.08%
Volume 862.9K
GEVA On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).

synageva biopharma corp (GEVA) Snapshot

Open
$214.94
Previous Close
$215.79
Day High
$218.80
Day Low
$214.94
52 Week High
05/22/15 - $218.80
52 Week Low
09/22/14 - $60.19
Market Cap
8.1B
Average Volume 10 Days
839.1K
EPS TTM
$-6.34
Shares Outstanding
37.2M
EX-Date
12/30/08
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SYNAGEVA BIOPHARMA CORP (GEVA)

synageva biopharma corp (GEVA) Related Bloomberg News

View More Bloomberg News

synageva biopharma corp (GEVA) Related Businessweek News

No Related Businessweek News Found

synageva biopharma corp (GEVA) Details

Synageva BioPharma Corp. operates as a biopharmaceutical company in the United States. It focuses on the discovery, development, and commercialization of therapeutic products for patients with rare diseases. The company’s lead program include sebelipase alfa, a recombinant form of human lysosomal acid lipase (LAL) under the Kanuma brand name for the treatment of LAL deficiency in infants, children, and adults. It also has various other research programs in various stages of preclinical development, including SBC-103, an enzyme replacement therapy in a Phase 1/2 study for lysosomal storage disease, known as mucopolysaccharidosis type IIIB; SBC-105, an enzyme replacement therapy in preclinical development for rare disorders of calcification; and other programs. The company was founded in 1996 and is headquartered in Lexington, Massachusetts.

282 Employees
Last Reported Date: 02/26/15
Founded in 1996

synageva biopharma corp (GEVA) Top Compensated Officers

Chief Executive Officer, President, Secretary...
Total Annual Compensation: $631.2K
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $374.9K
Chief Operating Officer
Total Annual Compensation: $210.8K
Chief Medical Officer, Head of Research & Dev...
Total Annual Compensation: $406.7K
Executive Vice President of Global Medical an...
Total Annual Compensation: $379.6K
Compensation as of Fiscal Year 2014.

synageva biopharma corp (GEVA) Key Developments

Alexion Pharmaceuticals, Inc., Synageva BioPharma Corp. - M&A Call

To discuss the acquisition transaction between Alexion Pharmaceuticals, Inc. and Synageva BioPharma Corp

Synageva BioPharma Corp. Proposes Amendment to Bylaws

Synageva BioPharma Corp. announced that it will propose amendment to company Bylaws to adopt a forum selection clause at the Annual Meeting of Stockholders to be held on June 26, 2015.

Synageva BioPharma Corp Announces Consolidated Earnings Results for the First Quarter Ended March 31, 2015; Reiterates Operating Expenses Guidance for the Year of 2015

Synageva BioPharma Corp. announced consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported total revenue of $927,000 compared to $1,586,000 a year ago. Loss from operations was $59,173,000 compared to $36,476,000 a year ago. Loss before provision from income taxes was $59,342,000 compared to $36,406,000 a year ago. Net loss was $59,601,000 compared to $36,424,000 a year ago. Basic and diluted net loss per common share was $1.63 compared to $1.16 a year ago. The company reiterates its total operating expenses guidance between $280 million and $295 million for 2015.  The total operating expense estimate is primarily due to investments supporting the global clinical development program for Kanuma, clinical development of SBC-103, preclinical development of SBC-105 and the bio-superior programs, expansion of the global clinical, medical affairs and commercial infrastructure, expansion of manufacturing capabilities, as well as advancement of other preclinical pipeline programs.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GEVA:US $218.11 USD +2.32

GEVA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for GEVA.
View Industry Companies
 

Industry Analysis

GEVA

Industry Average

Valuation GEVA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1,364.6x
Price/Book 11.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1,267.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SYNAGEVA BIOPHARMA CORP, please visit www.synageva.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.